MedTrace Logo

Clinical Trial of Shugan Jieyu Capsule in Generalized Anxiety Disorder

NCT05772104 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 495

Last updated 2024-12-18

No results posted yet for this study

Summary

This is a randomized double-blind placebo-controlled phase 3 clinical trial to further validate the effectiveness and safety of Shugan Jieyu Capsules in treating generalized anxiety disorder.

Conditions

  • Generalized Anxiety Disorder

Interventions

DRUG

Shugan Jieyu Capsules

Oral, 4 Capsules, BID

DRUG

Shugan Jieyu Capsules Placebo

Drug: Shugan Jieyu Capsules Placebo, Oral，4 capsules，BID Drug: Placebo, Oral, 1 capsule, BID

Sponsors & Collaborators

  • Sichuan Jishengtang Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Gang Wang, MD · Beijing Anding Hospital Affiliated to Capital Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-17
Primary Completion
2025-02-28
Completion
2025-06-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05772104 on ClinicalTrials.gov